Having trouble accessing articles? Reset your cache.

Abiraterone acetate: Interim Phase III data

Interim data from the double-blind, international Phase III COU-AA-301 trial in 1,195 patients with CRPC previously treated with 1 or 2 chemotherapy regimens, at least 1 of which contained Taxotere docetaxel, showed that 1,000 mg once-daily abiraterone plus 5 mg

Read the full 400 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE